about
Trial WatchTrial Watch: Adoptive cell transfer for oncological indicationsTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyTargeting Tumor Cells with Anti-CD44 Antibody Triggers Macrophage-Mediated Immune Modulatory Effects in a Cancer Xenograft ModelTrial watch: Cardiac glycosides and cancer therapyStructural pathways of cytokines may illuminate their roles in regulation of cancer development and immunotherapy.The structural network of Interleukin-10 and its implications in inflammation and cancerTrial watch: Immunostimulatory cytokines in cancer therapy.Novel insights into the mechanism of action of lenalidomide.Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.Cytokines reinstate NK cell-mediated cancer immunosurveillance.Classification of current anticancer immunotherapiesTherapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer.Three steps to breaking immune tolerance to lymphoma: a microparticle approach.Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumorsAssociation between IL-10 polymorphisms (-1082A/G, -592A/C and -819T/C) and oral cancer risk.Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.Trial watch: Dendritic cell-based interventions for cancer therapyTrial watch: Prognostic and predictive value of the immune infiltrate in cancerTrial watch: Peptide vaccines in cancer therapyTrial watch: DNA vaccines for cancer therapy.Trial Watch: Adoptive cell transfer for anticancer immunotherapy.Trial watch: Oncolytic viruses for cancer therapyPhase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapyPost-transcriptional regulation of cytokine signaling by AU-rich and GU-rich elements.Side effects of cytokines approved for therapy.Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias.Role of NK cells in immunotherapy and virotherapy of solid tumors.Cancer immunotherapy turns viralImmuno-modulatory Effect of IFN-gamma in AMD and its Role as a Possible Target for Therapy.Victories and deceptions in tumor immunology: Stimuvax(®)Rejuvenated T cells attack old tumorsTrial Watch: Peptide vaccines in cancer therapy.Trial Watch: Lenalidomide-based immunochemotherapy.Trial Watch: Anticancer radioimmunotherapy.Trial watch: Dendritic cell-based interventions for cancer therapy.Trial Watch: Toll-like receptor agonists for cancer therapy.Trial Watch: Radioimmunotherapy for oncological indications.Tumor-associated myeloid cells: new understandings on their metabolic regulation and their influence in cancer immunotherapy.
P2860
Q24618653-AAF3CC67-BE1B-4E77-A954-BF5070A79EB5Q26785545-26184472-2D5B-426D-BB45-A7C7991EAFDEQ26993238-0603AEC9-E0D8-44D9-B815-BAD9493B31EBQ27333471-DB89C6B4-4E0C-47EA-A991-0262F0AA5620Q28395830-337370FC-2D19-4854-B683-D03CE027F648Q33820227-6A76EB85-067E-4147-8477-26ABE6885EC9Q33851564-04D9856D-727A-4E7F-B63E-399655C39188Q33880165-37C94715-0D0E-4F76-AD47-50F26E2DE3DCQ34373253-C4C5EE08-C8DB-4CB5-ABCA-C17AA65B040DQ34859794-245B6CE3-D83F-42A3-8AE5-0FFA776EC85BQ35140082-AF20AD57-6D2A-46FF-ADE5-EF7DBBC8478EQ35149637-186D24E1-A9B3-4B1E-9888-8BCA327EC777Q35176800-A3B1AF0B-0CEC-48C7-9152-E66A890EFD91Q35328686-C0963844-2554-47BE-9BAB-B43934319F38Q35673240-4CA99622-0598-4F9D-9BEF-321136FC0198Q36182974-8BFF13E1-59CC-4678-BE5E-BECF20C26E00Q36373370-367C0F12-73E8-4227-B4A0-019D77637585Q36388529-C771FCE0-56D7-4831-9F24-396875613ECAQ36456483-B3E9759E-1FB6-4735-81D4-404CD88D3BEFQ36476100-057B9ED3-B33E-4ECD-BFF8-B2454019822DQ36845824-7AC302E9-B3A4-4AF9-8FC1-22A397709796Q36887833-4D9FBF17-69EA-4291-8387-279AB5131FE8Q37028023-704ED396-E7CC-4CA1-94A8-81D7AAC9EE8DQ37355213-B3D689A9-FDCA-4E3B-9B2B-A6B82CFA594DQ37652790-A856720E-D589-435E-9ED1-51D5E158E366Q37686196-D0D49B10-DDE9-4999-B0E8-737D73C4FD0EQ38255698-03A3CD2C-C8E3-4403-9B1E-442FB41E723BQ38569646-8CA54A20-2718-46A5-9996-56D5CFFEAE35Q38575116-C9144292-EECE-4070-AFC2-EABF6CC8C0ADQ40725853-B838D197-7499-43D7-B715-0670B2288F00Q41192179-6556C51B-FA7F-424A-9255-6DB7BDFFB3F1Q41968092-480B0E2B-080B-452E-B07B-5C2E3FDBE899Q42097613-2FCAE7CE-CF02-4B24-BDE4-CF35D00180CAQ42734544-F507A3A5-FACE-4F36-BD53-8556FC6352E1Q42737828-11ED91B5-F1FC-4E2A-AD36-EA3701F125DAQ42847992-2A2699EE-84BB-4398-BEB2-D9F65C0971A5Q42867339-938FD33A-9F19-4DA8-92F5-05650AFA779DQ42969291-C6E61E2B-0065-4154-8BCD-ED28DD578C27Q43104064-B5D0C2B4-DDC5-4D34-B16C-3EE450A982FBQ48638999-828F0EB1-F434-42CD-A7EA-4816EF84A625
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Trial Watch: Immunostimulatory cytokines.
@ast
Trial Watch: Immunostimulatory cytokines.
@en
type
label
Trial Watch: Immunostimulatory cytokines.
@ast
Trial Watch: Immunostimulatory cytokines.
@en
prefLabel
Trial Watch: Immunostimulatory cytokines.
@ast
Trial Watch: Immunostimulatory cytokines.
@en
P2860
P50
P356
P1433
P1476
Trial Watch: Immunostimulatory cytokines.
@en
P2860
P304
P356
10.4161/ONCI.20459
P50
P577
2012-07-01T00:00:00Z